<SEC-DOCUMENT>0000059478-24-000032.txt : 20240206
<SEC-HEADER>0000059478-24-000032.hdr.sgml : 20240206
<ACCEPTANCE-DATETIME>20240206070424
ACCESSION NUMBER:		0000059478-24-000032
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240206
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240206
DATE AS OF CHANGE:		20240206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		24598067

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20240206.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:lly="http://www.lilly.com/20240206" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20240206</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-51">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-52">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20240206.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1eb03c608c6345ebbbc1301605816863_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 6, 2024</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:17.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">317</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:3.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:2.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-23">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-24">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-26">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-27">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-29">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-30">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-31">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-32">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-33">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-34">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:Security12bTitle" id="f-35">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:TradingSymbol" id="f-36">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-37">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:Security12bTitle" id="f-38">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:TradingSymbol" id="f-39">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-40">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:Security12bTitle" id="f-41">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:TradingSymbol" id="f-42">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-43">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:Security12bTitle" id="f-44">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:TradingSymbol" id="f-45">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-46">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:Security12bTitle" id="f-47">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:TradingSymbol" id="f-48">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-49">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-50">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i1eb03c608c6345ebbbc1301605816863_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February&#160;6, 2024, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q423lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q423lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q423lillysalesandearningsp.htm">February 6, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q423lillysalesandearningsp.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:15.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.666%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 6, 2024</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q423lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icff0b5d9aae64aac89b1711ec6dce0de_1"></div><div style="min-height:103.68pt;width:100%"><div style="text-align:right"><img alt="logoa31a.jpg" src="logoa31a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Feb. 6, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Immediately</font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Jordan Bishop&#59; jordan.bishop&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div style="padding-left:36pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Joe Fletcher&#59; jfletcher&#64;lilly.com&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(317) 296-2884</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Revenue in Q4 2023 increased 28%. New Products</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Pipeline progress included </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">a </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Business development activity included the completed acquisitions of POINT Biopharma Global Inc. </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">and Mablink Biosciences SAS</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Q4 2023 EPS increased 13% to $2.42 on a reported basis and increased 19% to $2.49 on a non-GAAP basis, both inclusive of $0.62 of acquired IPR&#38;D charges.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2024</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">(i) Lilly defines New Products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">(ii) Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">INDIANAPOLIS, Feb. 6, 2024 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the fourth quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:160%">&#34;2023 was a year of tremendous achievement for Lilly, which delivered life-changing medicines to more patients than ever before resulting in strong revenue growth,&#34; said David A. Ricks, Lilly's chair and CEO. &#34;We advanced our pipeline of new medicines for serious diseases and created new partnerships and innovative ways of collaborating to add to that pipeline. Lilly invested in the quality, reliability and resilience of our supply chain with new advanced manufacturing plants and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#124; Lilly Corporate Center &#124; Indianapolis, Indiana 46285 &#124; U.S.A.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:160%">lines in the U.S. and in Europe. Entering 2024, we remain focused on the opportunity in front of us, to help solve some of the most challenging healthcare problems in the world and make life better for millions of patients.&#34;</font></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_4"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly has had numerous updates recently on key regulatory, clinical, business development and other events, including&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">U.S. Food and Drug Administration (FDA) approval of Zepbound</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> (tirzepatide) for the treatment of adult patients with obesity or overweight with weight-related comorbidities&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">FDA approval of Jaypirca</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL&#47;SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, under the Accelerated Approval Program&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:12.53pt">Positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), which met its primary endpoint where up to 74% of participants achieved an absence of MASH with no worsening of fibrosis at 52 weeks, compared to nearly 13% of participants on placebo&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#221f1f;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#221f1f;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Negative Phase 3 CYCLONE-2 results, in which Verzenio added to abiraterone did not meet the primary endpoint of improved radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC)&#59; the overall safety and tolerability profile was consistent with the known profiles of the medicines&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Approval of Ebglyss</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> (lebrikizumab) for adult and adolescent patients with moderate-to-severe atopic dermatitis in the European Union and Japan (Almirall S.A. has licensed the rights from Lilly to develop and commercialize Ebglyss in Europe)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Announcement of LillyDirect</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, the company&#8217;s end-to-end digital healthcare experience&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">Announcement of further expansion of the company&#8217;s injectable manufacturing capacity with a planned investment of $2.5 billion to build a site in Germany&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Completion of the acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The sixth consecutive 15% annual increase in Lilly's quarterly dividend, more than doubling </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">the dividend since 2018&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Announcement of Johna Norton, Lilly executive vice president of Global Quality, retirement after 34 years of service with the company, effective July 31, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For information on important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.705%"><tr><td style="width:1.0%"></td><td style="width:50.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="15" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">9,353.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">7,301.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">28%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net income &#8211; Reported</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2,189.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,937.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Earnings per share &#8211; Reported</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net income &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2,249.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,893.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Earnings per share &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included below under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Fourth-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2023, worldwide revenue was $9.35 billion, an increase of 28% compared with Q4 2022, driven by increases of 16% due to higher realized prices, 11% in volume and 1% from the favorable impact of foreign exchange rates. Higher realized prices were driven by Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in the U.S., partially offset by lower realized prices for Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">. In the U.S., Mounjaro saw net price positively impacted by savings card dynamics compared with Q4 2022, as well as a favorable one-time change in estimates for rebates and discounts. The volume increase was primarily driven by growth from Mounjaro, Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Zepbound, Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, partially offset by declines in Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Trulicity. New Products revenue grew by $2.19 billion to $2.49 billion in Q4 2023. Growth Products revenue increased 9% to $5.27 billion in Q4 2023. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 39% to $6.46 billion, driven by a 27% increase in realized prices and a 12% increase in volume. The higher realized prices in the U.S. were driven by Mounjaro, partially offset by lower realized prices for Humalog and Trulicity. When excluding Mounjaro, realized prices in the U.S. declined by high-single digits for the quarter. The increase in U.S. volume was driven by Mounjaro, Zepbound, Verzenio, Jardiance and Taltz, partially offset by a decrease in Trulicity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. increased 10% to $2.90 billion, driven by a 10% increase in volume and a 3% increase from the favorable impact of foreign exchange rates, partially offset by a 3% decrease due to lower realized prices. The increase in volume outside the U.S. was driven by Verzenio, Mounjaro, Jardiance, Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Taltz. Revenue also benefited from $65 million associated with milestones for the EU approval and launch of Ebglyss. These drivers were partially offset by approximately $130 million of one-time revenue in 2022 associated with the sale of the company's rights to Alimta in Korea and Taiwan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin increased 31% to $7.57 billion in Q4 2023. Gross margin as a percent of revenue was 80.9%, an increase of 2.1 percentage points. The increase in gross margin percent was primarily driven by higher realized prices, partially offset by increased manufacturing expenses related to labor costs and investments in capacity expansion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2023, research and development expenses increased 28% to $2.56 billion, or 27% of revenue, primarily driven by development expenses for late-stage assets and additional investments in early-stage research, as well as higher incentive compensation costs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses increased 17% to $1.92 billion in Q4 2023, primarily driven by costs associated with launches of new products and indications, as well as higher incentive compensation costs.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2023, the company recognized acquired in-process research and development (IPR&#38;D) charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of $622.6 million compared with $240.1 million in Q4 2022. The Q4 2023 charges primarily related to the acquisition of Mablink Biosciences SAS and the business development transaction with Beam Therapeutics Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was $121.0 million of income in Q4 2023, compared with $260.0&#160;million of income in Q4 2022. The decrease in income was driven by lower net gains on investments in equity securities in Q4 2023 compared with Q4 2022 and, to a lesser extent, higher net interest expenses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 12.7% in Q4 2023 compared with 7.6% in Q4 2022. The higher effective tax rate for Q4 2023 was primarily driven by a lower net discrete tax benefit compared with Q4 2022 and the new Puerto Rico tax regime.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2023, net income and earnings per share (EPS) were $2.19 billion and $2.42, respectively, compared with net income of $1.94&#160;billion and EPS of $2.14 in Q4 2022. EPS in Q4 2023 </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">included </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.62</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.23</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q4</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2022</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">. </font></div><div><font><br></font></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Fourth-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q4 2023 gross margin increased 31% to $7.69 billion. Gross margin as a percent of revenue was 82.3%, an increase of 1.8 percentage points. The increase in gross margin percent was primarily driven by higher realized prices, partially offset by increased manufacturing expenses related to labor costs and investments in capacity expansion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 13.1% in Q4 2023 compared with 7.3% in Q4 2022. The higher effective tax rate for Q4 2023 was primarily driven by a lower net discrete tax benefit compared with Q4 2022 and the new Puerto Rico tax regime.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q4 2023 net income and EPS were $2.25 billion and $2.49, respectively, compared with net income of $1.89 billion and EPS of $2.09 in Q4 2022. Non-GAAP EPS in Q4 2023 included</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.62</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.23 in</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q4</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2022</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.705%"><tr><td style="width:1.0%"></td><td style="width:50.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth Quarter</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.42</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">13%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net gains on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.09</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">19%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.62&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.23&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_13"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:22.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Fourth Quarter</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Year-to-Date</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,669.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,936.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(14)%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,132.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,439.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(4)%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Mounjaro</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,205.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">279.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5,163.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">482.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,145.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">808.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">42%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3,863.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,483.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">56%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">784.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">707.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,759.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,482.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">798.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">612.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,744.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,066.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">33%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">366.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">548.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(33)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,663.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,060.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(19)%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">253.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">277.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">974.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">971.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">243.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">205.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">922.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">830.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">186.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">175.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">678.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">650.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">113.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">57.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">98%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">393.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">293.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">34%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">73.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">64.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">253.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">191.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">32%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">44.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">236.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(81)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">217.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">927.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(77)%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Zepbound</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">175.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">175.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">38.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(100)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,023.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(100)%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9,353.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,301.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">28%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">34,124.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">28,541.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab, and were made pursuant to EUAs or similar regulatory authorizations </font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Trulicity revenue decreased 14% compared with Q4 2022 to $1.67 billion. U.S. revenue decreased 18% to $1.26 billion, driven by decreased volume and lower realized prices. Lilly has experienced and continues to expect intermittent delays fulfilling orders of Trulicity. These delays have impacted and are expected to continue to impact volume. Revenue outside the U.S. increased 1% to $413.6 million, driven by increased volume and the favorable impact of foreign exchange rates, largely offset by lower realized prices. Volumes in international markets continue to be affected by actions Lilly has taken to manage demand amid tight supply, including measures to minimize impact to existing patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Mounjaro</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Mounjaro revenue was $2.21 billion compared with $279.2 million in Q4 2022. U.S. revenue was $2.11 billion compared with $256.7 million in Q4 2022 reflecting higher realized prices due to decreased utilization of savings card programs as access continued to expand, as well as increased demand. U.S. revenue in Q4 2023 represented a sequential increase of $828.1 million, or 65%, compared with U.S. revenue of $1.28 billion in Q3 2023. Q4 2023 U.S. Mounjaro revenue also benefited from a favorable one-time change in estimates for rebates and discounts. Adjusting for this one-time change, sequential net sales would have grown by approximately 30% in Q4. Lilly has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand, which is expected to affect volume. Revenue outside the U.S. was $100.5 million compared with $22.5 million in Q4 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Verzenio revenue increased 42% compared with Q4 2022 to $1.15 billion. U.S. revenue was $774.8 million, an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of 40%, driven by increased demand and higher realized prices. Revenue outside the U.S. was $370.6 million, an increase of 45%, driven by increased demand and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Taltz revenue increased 11% compared with Q4 2022 to $784.6&#160;million. U.S. revenue increased 5% to $537.8&#160;million, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased 26%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $246.8 million, driven by increased volume.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, the company's worldwide Jardiance revenue increased 30% compared with Q4 2022 to $798.1 million. U.S. revenue was $468.9 million, an increase of 29%, driven by increased demand. Revenue outside the U.S. was $329.1 million, an increase of 32%, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Humalog revenue decreased 33% compared with Q4 2022 to $366.6 million. U.S. revenue was $167.6 million, a decrease of 50%, driven by lower realized prices primarily due to a one-time impact related to the implementation of list price decreases, partially offset by increased demand. Revenue outside the U.S. was $199.0 million, a decrease of 6%, driven by decreased volume, partially offset by the favorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Olumiant revenue increased 18% compared with Q4 2022 to $243.5 million. U.S. revenue increased 53% to $66.7 million, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. was $176.8 million, an increase of 9%, driven by increased volume.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Emgality revenue increased 6% compared with Q4 2022 to $186.1 million. U.S. revenue decreased 3% to $128.3&#160;million, driven by lower realized prices, largely offset by increased demand. Revenue outside the U.S. increased 33% to $57.8 million, driven by increased volume and higher realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Zepbound</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2023, worldwide Zepbound revenue was $175.8 million. Zepbound launched in the U.S. for the treatment of adult patients with obesity or overweight with weight-related comorbidities in November 2023. </font></div><div><font><br></font></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_16"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2024 Financial Guidance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company anticipates 2024 revenue to be in the range of $40.4 billion to $41.6 billion. The growth in revenue compared to 2023 is expected to be largely driven by New Products, partially offset by an expected continuation of the decline in Trulicity sales. The company continues to execute on its manufacturing expansion agenda, however, given strong demand and the time required to bring manufacturing capacity fully online, the company expects that demand for incretins is likely to outpace supply in 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's guidance now includes a new ratio calculated by subtracting research and development expenses and marketing, selling and administrative expenses from gross margin, and expressed as a percentage of revenue. The company anticipates this ratio to be 30% to 32% on a reported basis and 31% to 33% on a non-GAAP basis. Marketing, selling and administrative expenses are expected to continue growing in 2024, though at a pace slower than revenue growth with growth driven by marketing investments in recently launched and upcoming launch products. Research and development expenses are expected to increase at a higher rate than marketing, selling and administrative expenses in 2024, driven by investments in ongoing and new late-phase opportunities. </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Consistent with 2023, the company is not including any potential or pending acquired IPR&#38;D charges in its initial 2024 guidance and expects to update EPS guidance each quarter as acquired IPR&#38;D charges are incurred.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) is expected to be expense in the range of $400 million to $500 million, primarily driven by higher interest expense.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The 2024 effective tax rate is expected to be approximately 14%. This rate does not assume deferral or repeal of the provision in the 2017 Tax Act requiring capitalization and amortization of research and development for tax purposes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">EPS for 2024 is expected to be in the range of $11.80 to $12.30 on a reported basis and $12.20 to $12.70 on a non-GAAP basis. The company's 2024 financial guidance reflects adjustments shown in the reconciliation table below.  </font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.685%"><tr><td style="width:1.0%"></td><td style="width:75.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2024<br>Guidance</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$11.80 to $12.30</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.40</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$12.20 to $12.70</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company's 2024 financial guidance&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.608%"><tr><td style="width:1.0%"></td><td style="width:64.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2024 Guidance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$40.4 to $41.6 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(Gross Margin - OPEX</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">) &#47; Revenue&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(reported)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">30% to 32%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(non-GAAP)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">31% to 33%</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">($500) to ($400) million</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 14%</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$11.80 to $12.30</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$12.20 to $12.70</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above.</font></div></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses.</font></div></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_19"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q4 2023 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2024 financial guidance is provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly is a medicine company turning science into healing</font><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges&#58; redefining diabetes care&#59; treating obesity and curtailing its most devastating long-term effects&#59; advancing the fight against Alzheimer's disease&#59; providing solutions to some of the most debilitating immune system disorders&#59; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">To learn more, visit</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly.com and Lilly.com&#47;news.</font><font style="color:#1f497d;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;anticipate&#34;, &#34;may&#34;, &#34;could&#34;, &#34;aim&#34;, &#34;seek&#34;, &#34;will&#34;, &#34;continue&#34; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact and uncertain outcome of acquisitions and business development transactions and related costs&#59; intense competition affecting the company's products, pipeline or industry&#59; market uptake of launched products and indications&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto&#59; safety or efficacy concerns associated with the company's products&#59; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and an increasingly consolidated supply chain&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products, and risks from the proliferation of counterfeit or illegally compounded products&#59; the company's ability to protect and enforce patents and other intellectual property or changes in patent law or regulations related to data package exclusivity&#59; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; the use of artificial intelligence or other emerging technologies in various facets of the company's operations may exacerbate competitive, regulatory, litigation, cybersecurity and other risks&#59; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade disruptions, international tension, conflicts, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally&#59; devaluations in foreign currency exchange rates or changes in interest rates and inflation&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or activities&#59; changes in tax law and regulations, tax rates, or events that differ from our assumptions related to tax positions&#59; regulatory changes and developments&#59; regulatory actions regarding the company's operations and products&#59; regulatory compliance problems or government investigations&#59; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations&#59; asset impairments and restructuring charges&#59; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Ebglyss</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (lebrikizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jaypirca</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pirtobrutinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tirzepatide injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Omvoh</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(mirikizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Innovent)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Zepbound</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(tirzepatide injection, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third-party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:24.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.312%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December 31, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9,353.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,301.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34,124.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28,541.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">20%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,788.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,548.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,082.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,629.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,562.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,995.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9,313.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,190.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,924.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,643.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,403.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,440.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">622.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">240.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3,799.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">908.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">78%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">244.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(72)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,387.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,836.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,457.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,127.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(93.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(58.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(312.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(268.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">214.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">409.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(52.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">260.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(53)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">96.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(320.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,508.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,096.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,554.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,806.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">319.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">158.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,314.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">561.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,189.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,937.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,240.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,244.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(16)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(16)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">903,980&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">904,732&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">903,284&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">904,619&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icff0b5d9aae64aac89b1711ec6dce0de_25"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr><tr style="height:5pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Gross Margin - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">7,565.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,753.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">27,041.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">21,911.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Increase for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">124.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">506.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">574.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,694.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,877.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">27,548.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">22,485.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Gross Margin as a percent of revenue - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">80.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">78.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">79.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">76.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin as a percent of revenue - Non-GAAP</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">82.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Non-GAAP gross margin as a percent of revenue reflects the gross margin effects of the adjustments presented above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Net Income - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2,189.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,937.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,240.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6,244.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">124.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">506.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">574.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">244.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on investments in equity securities (Other income&#47;expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(117.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(216.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">385.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Corresponding tax effects (Income taxes)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(126.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(263.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net Income - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,249.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,893.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,712.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,186.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Effective tax rate - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">12.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">7.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">20.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate - Non-GAAP</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share (diluted) - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2.42</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5.80</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6.90</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share (diluted) - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">For the twelve months ended December 31, 2022, excluded charges primarily include the intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Non-GAAP tax rate reflects the tax effects of the adjustments presented above.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20240206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:04ff7879-5e01-48f1-9502-6f6621993a4f,g:d91da419-3fc2-49a7-8d1b-6d16ad200179-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20240206" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20240206">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20240206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20240206_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20240206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20240206_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:04ff7879-5e01-48f1-9502-6f6621993a4f,g:d91da419-3fc2-49a7-8d1b-6d16ad200179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20240206.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_256f6691-a4f0-4d28-814b-67547992a508_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:to="loc_us-gaap_ClassOfStockDomain_256f6691-a4f0-4d28-814b-67547992a508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:to="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d06846c6-e4bb-4a94-9df1-8b454a4c0302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_us-gaap_CommonClassAMember_d06846c6-e4bb-4a94-9df1-8b454a4c0302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_04f767ff-520c-421f-a28f-7b85d24c96cf" xlink:href="lly-20240206.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A718NotesDueJune12025Member_04f767ff-520c-421f-a28f-7b85d24c96cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_d50e0b8c-c68d-4d51-bb62-05a663e2da00" xlink:href="lly-20240206.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1.625NotesDueJune22026Member_d50e0b8c-c68d-4d51-bb62-05a663e2da00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_708c81da-f960-4146-9a64-2e8c03fd0584" xlink:href="lly-20240206.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A2.125NotesDueJune32030Member_708c81da-f960-4146-9a64-2e8c03fd0584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_c1d942e7-1f80-428a-9e59-b1b821c818d0" xlink:href="lly-20240206.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A625Notesdue2031Member_c1d942e7-1f80-428a-9e59-b1b821c818d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_77eb8c62-db65-4443-9e20-880815782439" xlink:href="lly-20240206.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_77eb8c62-db65-4443-9e20-880815782439" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_7529b346-1039-48f9-baea-0d55460361a4" xlink:href="lly-20240206.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1.700Notesdue2049Member_7529b346-1039-48f9-baea-0d55460361a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_3ba38e3c-d66f-4bcd-b4b1-b81ec2d89cef" xlink:href="lly-20240206.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A500NotesDue2033Member_3ba38e3c-d66f-4bcd-b4b1-b81ec2d89cef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_1706cf50-abd5-4c5b-8049-e229b24095a5" xlink:href="lly-20240206.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1625NotesDue2043Member_1706cf50-abd5-4c5b-8049-e229b24095a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_ed17fa41-3e47-48a6-8456-dee659741e60" xlink:href="lly-20240206.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1125NotesDue2051Member_ed17fa41-3e47-48a6-8456-dee659741e60" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_2f2a402b-3374-4a42-92a3-ceb59394da99" xlink:href="lly-20240206.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1375NotesDue2061Member_2f2a402b-3374-4a42-92a3-ceb59394da99" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_37ca91ff-d2b4-425c-9f5c-b1bb21759855" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_DocumentType_37ca91ff-d2b4-425c-9f5c-b1bb21759855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_091bd9ae-c5d4-429a-b3cd-29084058d8b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_DocumentPeriodEndDate_091bd9ae-c5d4-429a-b3cd-29084058d8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7869d25d-ed55-447e-b69f-b6571f7cb32a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7869d25d-ed55-447e-b69f-b6571f7cb32a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ab513f1e-5d90-4881-8f49-e9d3cb0cb060" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityFileNumber_ab513f1e-5d90-4881-8f49-e9d3cb0cb060" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e282c4ed-0232-4fd2-9632-7aafc62426fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityTaxIdentificationNumber_e282c4ed-0232-4fd2-9632-7aafc62426fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d1d4514f-4c4c-4367-94f2-74c3d378c3cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressAddressLine1_d1d4514f-4c4c-4367-94f2-74c3d378c3cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9be7529c-b2f5-4cd5-83ab-ac82a5b202b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressCityOrTown_9be7529c-b2f5-4cd5-83ab-ac82a5b202b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16a657ca-61d3-4c95-aec0-7e2a126ab55a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressStateOrProvince_16a657ca-61d3-4c95-aec0-7e2a126ab55a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c288b548-3d1e-4387-b4f0-ab812cd47af7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressPostalZipCode_c288b548-3d1e-4387-b4f0-ab812cd47af7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_900d6677-8d78-45fc-a5df-b67a17878870" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_CityAreaCode_900d6677-8d78-45fc-a5df-b67a17878870" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bb4f6616-2ee3-476e-91f7-e610e607ef0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_LocalPhoneNumber_bb4f6616-2ee3-476e-91f7-e610e607ef0b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_c53a6ba8-eba5-4676-8b1d-ce960555b765" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_WrittenCommunications_c53a6ba8-eba5-4676-8b1d-ce960555b765" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_dc446cc9-7904-4b54-ab16-39206db8ded0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_SolicitingMaterial_dc446cc9-7904-4b54-ab16-39206db8ded0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_65bdc750-c7d2-49e0-91f6-afd2e19dc0e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_PreCommencementTenderOffer_65bdc750-c7d2-49e0-91f6-afd2e19dc0e2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9b693f9d-ff70-4565-b163-8694458019d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9b693f9d-ff70-4565-b163-8694458019d7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c25a7e0e-eae1-4e3e-bb60-50699705b65d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityEmergingGrowthCompany_c25a7e0e-eae1-4e3e-bb60-50699705b65d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_89c1d3cf-746b-4762-81aa-0b85fa5169d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_Security12bTitle_89c1d3cf-746b-4762-81aa-0b85fa5169d7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_642712fd-f117-4776-b781-10e99ed4b7b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_TradingSymbol_642712fd-f117-4776-b781-10e99ed4b7b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bd870b09-067e-4791-bfbd-1baea0deb082" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_SecurityExchangeName_bd870b09-067e-4791-bfbd-1baea0deb082" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1eff228a-4038-4080-a97b-cd8f5a37aceb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityRegistrantName_1eff228a-4038-4080-a97b-cd8f5a37aceb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_68bbf864-fd8e-4f41-9b2b-74e210c253cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityCentralIndexKey_68bbf864-fd8e-4f41-9b2b-74e210c253cc" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ecff91c4-8ba0-4d0e-bd64-4bb4fdc5ffe9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_AmendmentFlag_ecff91c4-8ba0-4d0e-bd64-4bb4fdc5ffe9" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20240206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:04ff7879-5e01-48f1-9502-6f6621993a4f,g:d91da419-3fc2-49a7-8d1b-6d16ad200179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lly_A1125NotesDue2051Member_e608c018-b437-4c59-9388-d8d31751b77d_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20240206.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_326eef29-719b-43e1-bcf4-b10205e34597_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20240206.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_4fddc7f5-f0e5-405d-8354-c59d3096d658_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20240206.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_ada90e0c-f6f6-4738-b1ab-b61fcc10249c_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20240206.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_89f7323d-e951-4753-b6a9-937b53ac8157_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_96c80424-585f-4518-aa24-e6db46849a6c_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20240206.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0bd30e83-2b46-4c87-a69c-405014f24030_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4fbe0478-a285-4ee3-be44-6b19bb9a7bfc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_64d7c0f7-aabb-41c5-a6a2-563d9817d04d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_70834031-e1d8-4ee9-a8f4-4349c03ee398_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ed44c722-2912-485b-928b-f39f401de6cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_51e31c29-1656-498c-aea0-d2158e253efd_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20240206.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_044f8b0a-9187-4047-b069-50f91697f858_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20240206.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8f5b66bb-5eae-45a4-9ba4-dc1b6a7daa2b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_7c3bc3fb-23ee-4939-b97f-0c4e6f7af737_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20240206.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ad301ccc-d3c1-427b-b355-541a4ea65889_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_05adb64d-7901-44f0-8642-d7de4c96b5ef_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20240206.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f2cdeafb-9926-41e4-a0f4-769ed6baa601_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a5b5588-4ac9-468e-9aee-646e338852c3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_fc992fc6-1193-4fc4-bc98-162f0be437cb_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_cf521d24-8a75-489c-abfa-d295bcd76101_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7919377e-9327-450e-87a5-7de3b1181882_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_61ce1599-b9cc-4f61-8a41-d747e896bae0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7f51e92d-68ab-4a11-81d6-f1b0ee0efd90_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_63852a77-80bd-47cb-8c5e-8b9a44085d25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3d459891-f895-4664-8e45-b7e26c13eb0b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_947e2773-a884-4ca1-9f8a-576bee75bb73_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_64078d07-5f39-41e2-9ec7-7159309072c8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_8b35d6a6-64c2-4238-b6cb-419b9982af3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_169dd7ce-3230-4159-b4ac-3bb46d46bf73_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8f118155-a2f9-492d-aa5b-de8bbe2821b3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_7d245d34-3a79-41c8-b3d6-d656edaf5cad_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20240206.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_577b46d0-af3a-4dda-b779-e41d981ce6db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_07552a99-c7b1-45f2-a83e-6b36f5eb366c_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_794026b3-a626-4fdf-8878-25ef568c13bd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ae6f7d44-726c-433b-8e11-344069ace10c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_378af808-366a-4007-b244-1a89c1c90b58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ba3eaf1e-139f-4882-b976-a4cf0b152c58_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20240206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:04ff7879-5e01-48f1-9502-6f6621993a4f,g:d91da419-3fc2-49a7-8d1b-6d16ad200179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20240206.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8688ba24-8a22-4208-9b5a-1bf556d26478" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8688ba24-8a22-4208-9b5a-1bf556d26478" xlink:to="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256f6691-a4f0-4d28-814b-67547992a508" xlink:to="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d06846c6-e4bb-4a94-9df1-8b454a4c0302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_us-gaap_CommonClassAMember_d06846c6-e4bb-4a94-9df1-8b454a4c0302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_04f767ff-520c-421f-a28f-7b85d24c96cf" xlink:href="lly-20240206.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A718NotesDueJune12025Member_04f767ff-520c-421f-a28f-7b85d24c96cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_d50e0b8c-c68d-4d51-bb62-05a663e2da00" xlink:href="lly-20240206.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1.625NotesDueJune22026Member_d50e0b8c-c68d-4d51-bb62-05a663e2da00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_708c81da-f960-4146-9a64-2e8c03fd0584" xlink:href="lly-20240206.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A2.125NotesDueJune32030Member_708c81da-f960-4146-9a64-2e8c03fd0584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_c1d942e7-1f80-428a-9e59-b1b821c818d0" xlink:href="lly-20240206.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A625Notesdue2031Member_c1d942e7-1f80-428a-9e59-b1b821c818d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_77eb8c62-db65-4443-9e20-880815782439" xlink:href="lly-20240206.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_77eb8c62-db65-4443-9e20-880815782439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_7529b346-1039-48f9-baea-0d55460361a4" xlink:href="lly-20240206.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1.700Notesdue2049Member_7529b346-1039-48f9-baea-0d55460361a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_3ba38e3c-d66f-4bcd-b4b1-b81ec2d89cef" xlink:href="lly-20240206.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A500NotesDue2033Member_3ba38e3c-d66f-4bcd-b4b1-b81ec2d89cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_1706cf50-abd5-4c5b-8049-e229b24095a5" xlink:href="lly-20240206.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1625NotesDue2043Member_1706cf50-abd5-4c5b-8049-e229b24095a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_ed17fa41-3e47-48a6-8456-dee659741e60" xlink:href="lly-20240206.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1125NotesDue2051Member_ed17fa41-3e47-48a6-8456-dee659741e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_2f2a402b-3374-4a42-92a3-ceb59394da99" xlink:href="lly-20240206.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbb1c71-d5e9-412d-b0ff-18e059613e3d" xlink:to="loc_lly_A1375NotesDue2061Member_2f2a402b-3374-4a42-92a3-ceb59394da99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_413e1b6b-2596-491e-99e9-dbd26c023ad3" xlink:to="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_37ca91ff-d2b4-425c-9f5c-b1bb21759855" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_DocumentType_37ca91ff-d2b4-425c-9f5c-b1bb21759855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_091bd9ae-c5d4-429a-b3cd-29084058d8b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_DocumentPeriodEndDate_091bd9ae-c5d4-429a-b3cd-29084058d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7869d25d-ed55-447e-b69f-b6571f7cb32a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7869d25d-ed55-447e-b69f-b6571f7cb32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ab513f1e-5d90-4881-8f49-e9d3cb0cb060" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityFileNumber_ab513f1e-5d90-4881-8f49-e9d3cb0cb060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e282c4ed-0232-4fd2-9632-7aafc62426fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityTaxIdentificationNumber_e282c4ed-0232-4fd2-9632-7aafc62426fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d1d4514f-4c4c-4367-94f2-74c3d378c3cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressAddressLine1_d1d4514f-4c4c-4367-94f2-74c3d378c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9be7529c-b2f5-4cd5-83ab-ac82a5b202b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressCityOrTown_9be7529c-b2f5-4cd5-83ab-ac82a5b202b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16a657ca-61d3-4c95-aec0-7e2a126ab55a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressStateOrProvince_16a657ca-61d3-4c95-aec0-7e2a126ab55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c288b548-3d1e-4387-b4f0-ab812cd47af7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityAddressPostalZipCode_c288b548-3d1e-4387-b4f0-ab812cd47af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_900d6677-8d78-45fc-a5df-b67a17878870" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_CityAreaCode_900d6677-8d78-45fc-a5df-b67a17878870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bb4f6616-2ee3-476e-91f7-e610e607ef0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_LocalPhoneNumber_bb4f6616-2ee3-476e-91f7-e610e607ef0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_c53a6ba8-eba5-4676-8b1d-ce960555b765" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_WrittenCommunications_c53a6ba8-eba5-4676-8b1d-ce960555b765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_dc446cc9-7904-4b54-ab16-39206db8ded0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_SolicitingMaterial_dc446cc9-7904-4b54-ab16-39206db8ded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_65bdc750-c7d2-49e0-91f6-afd2e19dc0e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_PreCommencementTenderOffer_65bdc750-c7d2-49e0-91f6-afd2e19dc0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9b693f9d-ff70-4565-b163-8694458019d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9b693f9d-ff70-4565-b163-8694458019d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c25a7e0e-eae1-4e3e-bb60-50699705b65d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityEmergingGrowthCompany_c25a7e0e-eae1-4e3e-bb60-50699705b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_89c1d3cf-746b-4762-81aa-0b85fa5169d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_Security12bTitle_89c1d3cf-746b-4762-81aa-0b85fa5169d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_642712fd-f117-4776-b781-10e99ed4b7b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_TradingSymbol_642712fd-f117-4776-b781-10e99ed4b7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bd870b09-067e-4791-bfbd-1baea0deb082" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_SecurityExchangeName_bd870b09-067e-4791-bfbd-1baea0deb082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1eff228a-4038-4080-a97b-cd8f5a37aceb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityRegistrantName_1eff228a-4038-4080-a97b-cd8f5a37aceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_68bbf864-fd8e-4f41-9b2b-74e210c253cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_EntityCentralIndexKey_68bbf864-fd8e-4f41-9b2b-74e210c253cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ecff91c4-8ba0-4d0e-bd64-4bb4fdc5ffe9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fdec0f8b-119e-4743-81b6-e0272294a840" xlink:to="loc_dei_AmendmentFlag_ecff91c4-8ba0-4d0e-bd64-4bb4fdc5ffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31a.jpg
<TEXT>
begin 644 logoa31a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
MX)O_ !%_;\\<K;>%-+:S\.VMR(=6\2WH"Z?I_0G'_/:7 SY4?/SIGRX_WE?H
M=^P]_P &V6D^&'L]:^.6N_V]= B8>&M'N)(;,=<_:;CAY.WR1[,%!^\<9%?I
MM&G@W]G7X;6]NO\ PCO@GPEH-OY40_<Z9INGQCL/NQQK]*^GPO#6+QU3ZUFT
MVEVZV_**/P?/_&OA[AC!?V#X?8=3EMSJ+Y%+175_>JROU;M>VLH^Z>4_L+_\
M$]/ /_!/SX9-HOA>U^U:OJ0#:SKUV,WNKS#GG&?+B'\$*<#J<N7D?Z.KF?!/
MQ!T7XD>%K?5O#NN:9X@TNZ'[B^L+B.ZAF'M)&2OY5TU?H%"C2I4U"BDHK:VQ
M_)&;9ECL?C*F+S*<IUI.\G*][^=]5;HMDK)605^:?_!9?_@LLO[*VF77PX^&
M=U;77Q&NX#_:&H ^;#X9B?CMP]T>PZ1CDY/%>E?\%D?^"F-I^P9\%6TK0;JW
M?XH>,898-'C9!,-(A^Z]^Z$8^3CRU;AY,\.D<@'X/_!3X->,_P!L;X]:;X9\
M.VMYKOBKQ5J.6FN)GER7.^>>67G]V,O)(Y]Z^0XES^5&2P.#UJ2W:W5^B\W^
M'S/Z)\#_  DPV8TGQ3Q(E'!T[N,9:*?+?FG+I[.-NOQ/R7O7/@5\!O'7[9_Q
MOM?#'A:SN_$7BW7)YKVZN9II#@>9F>[N)VR53+_.[\DOCEWY_<3]E;_@G]\'
M_P#@CM\ =4^(WBR\L]4\3:+8?:-7\37$(\R#.$^S649/R!W<(H_UDCR =-D:
M>G_L)_L(> O^"9O[/]Q;6MQ;2:E) M]XI\3WRK UR8TWO([O_JK>/YMB9P@R
M3\Y=S^0?_!9;_@JK<?MU?$=O"?A.YNK/X7^&;H_8 V8F\0W8RGVR1/X(N3Y<
M9Z(=[X=_+C\RG@Z&28?ZUB;3KR^%/6S_ ,EU9]IC.)<U\4L[>0Y&Y4,JI6]K
M->ZYQ6EG:UN9*T(?]O26EE\P?M1?'[6_VN?VA_$WC[6+?_B8>+]2^T"V@'F_
M9XN(X+=/[^R-(T_X!7]#7_!)G]DF7]C7]B'PGX9U*U6U\3:CG6M>7'S"\N0G
M[MQ_?AB2& _]<>*_-?\ X-__ /@FA)\9_B+:_&SQIII_X1'P?<Y\.VUQ#\NK
MZC'C_20?XHX&'4?\MQU_=O'7Z#?\%6_^"G>A_P#!/7X1,ME]GU3XC>)('30-
M)9CY<'4&]N>X@C/1!S(_R @>9)'MPSAXX:E4S?&NW-?5]F[M^KZ(\_QMSR>=
MX_">'/"]/F5)QYE';FC'EC"^RC3BVY-NR;ULXNW6?MX?\%*_AU_P3[\%K=^*
MKIM5\1:E ?[(\/V#)]MU C(+GM#"".9'.#@A!(_R5^*G[7'_  6N^/'[5FH7
M5O#XFO/ 7ALMNM]*\,W#V96+G_73_P"OFX^^/,$9Q]Q.:\(DE^(W[<G[1/S?
MVMX^^(GC?4>/^6UQ=S_I''%'&/\ 82-$_@C3C]EOV1_^"3'PA_X)G_!:]^*?
MQ@72_%?C#0;!M1U#4+J(3Z=H>P[Q':02#$DF_8B2.#(\@7RPA?:>>6/S#.:C
MCAW[.C'=[67F^NG1/2^I[6'X5X.\,,'2J9O36.S*K;D@DI-R;2M"$KJ*YG93
MDG.3^'>Q^&=EXIU*V\3#68-2O+?4A<^>-0%P_P!H\W_GIYGWZ_H3_P""&7[5
M'BS]J+]AJSU3QI>7FJ:UX8UFX\.MJ%RWFSW\*1P3Q/*Y^^X2=8]_5RGS_/FO
MP5_:4^--Q^T1\?/&7CBYMC:GQ1JUQJ9M_P#GWBDD/EQ_]LTPE?T5?\$H/V7;
MC]D#]A;P/X3U2U6R\130-JFLPLHW0W5TV\QO_MQIY<)_ZY5CP73FL?4<&W!)
MW??6R^_<]+Z36(PG^JV$6+I1CBISBXK1N"4;U$I63Y5=1>R;:=M%;Z?HHHK]
M./X5"BBB@ HHHH **** "BBB@ HHHH **P?&/C31_!6D_:]:U+3M)M>\UY<I
M#&#]6XKC]'_:W^%?B'4OLMC\3_A_>72C_4V_B"SED_(.36<JL(Z2:7S.JC@<
M36BYT:<I);M1;7WI6/3J^)?VKO\ @A5\!?VHM1FU.'0[KP#X@NL2W&H>&C':
MQW/!'[RW='@]\HB2?[=?:-E<PWL(GA93&1UJS6>*P=#$1Y*\5)>?]7._).(L
MTR:O]9RK$3HS[Q;5_)K:2\FFC\3?BI_P:T^-=+"_\(7\4/"NL=]NL:=<::1_
MP*'SZ\WU'_@VK_:"TU_WFK?#(PVXSYW]KS^5C_@=K7[]5^-O_!>/_@K>FLC4
M_@1\,]2WV^3;>+M6MIL>?V?3HW_N <3G_MGT\P'X[.,BRC!T'7J1:[)/=]E>
M_P _(_I/PX\6/$;B7,X95A*D)]9U)4U[D+ZRER\J\DDDV[+K=?E/XP\+_P#"
M(>,=1TR/4M)U3^S[F6#^T+!GFL[C8_\ K(7=$WQ^AKZ8_P""4_\ P3%U/_@H
MK\5+JWO;B^T+X?\ AN -J^K0*AE\Y_\ 5V\)?CS9.7/!$<:<_?3?X_\ LD?L
ML^*/VS/CKH/@'PE:;]4U-_\ 2+GEH=/M4_UEQ/C[L<?\]B#YW3/]*'[(_P"R
MOX6_8U^!>A^ O"5ILTW3!NN+@E?.U&Y?!DN9SW=SZ=!L081!7SG#.0_7:SK5
M5^ZB_O?;T[G[%XX>*[X6RV.68"HGCJJ5G9?NX]9M;<S::BFK7O+515_!?@/_
M ,$%_P!G+X$F"XG\+7?C;4K/E;GQ-?&\'XP((X'_ .!QFOKSPEX4TOP-H%OI
M6CZ;9Z3IMHOE06UE D,, _V$3A17045^I8? X?#JU""CZ*WX[_>?P;GG$V;9
MS5]KFN)G6?3GDY6]$W9>22T"OP>_X.6?B=XLU;]LS0?">H3W,?A/3_#T%[I=
MBK?N+F6:2<27'^_^[V?]LJ_07XK?\%O?@S\&_P!KVW^%NIZI=/;VH:VU?Q+#
MB73-(U#^&VE.,D<.)'3_ %<A1#D^9Y?L7[3W[&?PG_;R\&:.GCC0;/Q59VP^
MUZ3J%M<O%-#YBCF*>%P?+<!25SY;X4X->/G%&&:86>&PE1.46KZ]NC/T?P\Q
M]?@7/<+G?$&"G[&K"7(^76TEI."=DVENFT^65]FK_D'_ ,&W/Q$\3:7^W)<^
M&M-N+J3PWKV@74^L6N?W*B#RS#<[/[X=T3=Z3FOVY^.'Q@T']GWX5Z]XU\1W
M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140511616327632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ BSA&6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "+.$983BO_^^X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "+.$98F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (LX1EBL
MQB$!]P8  !0Q   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "+.$98GZ ;\+$"  #B#   #0
M    @ $Z#P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (LX1EB7BKL<P
M !,"   +              "  182  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M (LX1E@9117U-P$  "<"   /              "  ?\2  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "+.$98)!Z;HJT   #X 0  &@
M@ %C%   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "+
M.$9899!YDAD!  #/ P  $P              @ %(%0  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  "2%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20240206.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="lly-20240206.htm">lly-20240206.htm</File>
    <File>lly-20240206.xsd</File>
    <File>lly-20240206_def.xml</File>
    <File>lly-20240206_lab.xml</File>
    <File>lly-20240206_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lly-20240206.htm": {
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20240206",
   "dts": {
    "inline": {
     "local": [
      "lly-20240206.htm"
     ]
    },
    "schema": {
     "local": [
      "lly-20240206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20240206_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20240206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20240206_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 10,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 12,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 38,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 52
   },
   "report": {
    "R1": {
     "role": "http://www.lilly.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lly-20240206.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lly-20240206.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "lly_A1.625NotesDueJune22026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A1.625NotesDueJune22026Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625% Notes due 2026",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "documentation": "1.625% Notes Due June 2, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1.700Notesdue2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A1.700Notesdue2049Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.700% Notes due 2049",
        "label": "1.700% Notes due 2049 [Member]",
        "documentation": "1.700% Notes due 2049 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1125NotesDue2051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A1125NotesDue2051Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "documentation": "1.125% Notes due 2051"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1375NotesDue2061Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A1375NotesDue2061Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "documentation": "1.375% Notes due 2061"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1625NotesDue2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A1625NotesDue2043Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "documentation": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A2.125NotesDueJune32030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A2.125NotesDueJune32030Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.125% Notes due 2030",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "documentation": "2.125% Notes Due June 3, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A500NotesDue2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A500NotesDue2033Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "documentation": "0.500% Notes due 2033"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A6.77NotesDueJanuary12036Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.77% Notes due 2036",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A625Notesdue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A625Notesdue2031Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.625% Notes due 2031",
        "label": ".625% Notes due 2031 [Member]",
        "documentation": ".625% Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A718NotesDueJune12025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20240206",
     "localname": "A718NotesDueJune12025Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "7 1/8% Notes due 2025",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock (no par value)",
        "label": "Common Class A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000059478-24-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-24-000032-xbrl.zip
M4$L#!!0    ( (LX1E@BP'@R.Q,  #3$   0    ;&QY+3(P,C0P,C V+FAT
M;>U=ZW/B.K+_?OX*%:=V)ZD*QF\>R;#%(<RY[,DDJ9"Y>V:_; E;!.T8FV.;
M!.Y??[MEF_#&)N0!XZF:&4!R6^IN_;K5DEH7_Q@/'/+(_(![[N=/BB1_(LRU
M/)N[#Y\_-3K-=OO3/^J_7/1#J 95W: V=KC[XW.A'X;#6JGT]/0D/6F2YS^4
ME&JU6A*EA:CJ^DI(+JY4LQF?5AQW?4<*F"4]>(\E*"BILJHE%;'07JB+)%59
M-DM185)UJ8FSE;42%G=IP)+J?+RNLJ*5N O5V9^_W5U-J3N3N?H.AU\DRQM@
M<W59E<VDYB@H/E ZG-;NT: K*,<%<_WCX[ (?9\CG?#BN1&ET*=NT//\ 0U!
M9MA&HRA7BIHRY5/ 5W$>>JZ4_OQZU;'Z;$"+W U"ZEILEKM\ \\6ZT-K5]?>
MU%15+LIJ45$%D9I#0<D*S"U^ZQ3J%WU&[?K%@(64(-DB^VO$'S\7FIX;,C<L
MWD^&\&XK^O:Y$+)Q6!)J5*K_\LLO%R$/'58'.103&5R4HM\N2A'EKF=/ZA<V
M?R1!.''8YX+-@Z%#)S77<QF\GX]K6)'YT4=NV\P5'Z'\>C1@/K>BUX_#.];[
M7+"*P'&7#I 2X[66"Z^;-*%Q/G7:KLW&?[!)@7#[<Z%7-)1"7<8_1E4O5RY*
M<U0SO*0Q8*X-?\,O#GV8$E<+]1YU K9$MS3?$9_UF ^CFP4KV(]CHA8(W8 W
M$S&.:R$P_7,AX(.A@X(7O_5];-@LIZ5Q8(,8Q.N>WQ&_,O!&OO@F%*P6=TXT
M'3N7_,X$^Y)OW,;O/<Y\(IK$5@Z*9ON/>;8N/EQ/?IJG/@3N>';R#=3:#R]I
MR.K8']1/U)W%LFDS[355DY+D>_*2TER_5[-!?6TVQ+UA#Z@[T5<;7C8>.MSB
MX5<VZ,(K; ZEP@X48GBJ=4+H$C[3=&@0W/0ZH6?]:(QY4*@G59K>8."YHKP1
M$;HHK:0_9<6T&8<A'.T A0.CL]8H*Y5K+V3!Y8C]<^0R!=AB'*6$]$.5D"*9
MJC$K(Q488QZEC(Q#E9$J*?,RTE19DX]21N:ARB@91?:(@7"4HQ1.^5"%8\AR
M,GQ .-I1"J=RJ,(QI7)Y"F[4'5%_ GZ"=IPVJ'JH4E)FW 15UH]S#"GRP8I'
M*L<8)PR07CU.^;SZ9/W5Y*/,#A_C./T#Y1"#")%XM/*,>,S#%T]I/O!5FHDL
MEFS^& 4A46I<85U9LTRY8IF:;K!NMVLIFJR8LE%1S(JI_0?'W/,S<>!RP-UB
MG_&'?EC35:EL#,/S)VZ'_9HBRW\KB*KUBV!(W?I%U\>X7/0YHK-$#6/.16BW
M3ZVP%HP& _ !SK$C1>KP![=F 6>97X@H)@]9GN/YM5^%PLCG/>AYL4<'',3Y
MZ1XT("#7[(G<>0/J?CH+J!O 2WS>BRH&_/]835&AU>+K4]P3H(.!XZ1GX(9
M7_[^*S#C?+X'LYR@_@,P(_2&-44"BM#*D'8=EI1W/1_87H36.G08L%KRX3R)
M_4;!ZJ)XZ#RFUO7"T!O4D*V/S ^Y19V8%8(K4?$SQR4YXGH(X@WMY,UQL01%
MI16_RY)1-586R9*R^I$UI,JZI&F5O9!2P)"9Y8VD2J*744^!F2B6SP6ML,!O
ME(<V#(GMC5 8J";G0VKCHE)-)@K(J?0""NIPC#1F==1AO25A17(JS.G+ZZNU
MOJ#6Y46U%LKR[;I]W[HDG?O&?:NS5KL_2FL[K>:WN_9]N]4AC>M+TOJS^3^-
MZ]];I'GS]6N[TVG?7+]C%^147?@7#?J@.Z'GGI%+J2D1\ /TZ@(RAO8^]%H,
MD9) E)0,>5O(*AN2HIM9$4N%F:*Z&DZRPHRN2Z92W0LIU9 T<W71 F(EA8E6
M&)&Q6"GM;% 5\QZJDL!SN)T)[C)JSXR]JZ"]>P,[7=DVOH2=_G)S]Y6D7\>\
M]*P1>F_1HFZTC FN3J7XQ_(:9C1$7[=3.SD?^5#.A_*+AW+\2E6,YEEW5GZ3
MT;W5 1 # <S_7>OZGMRU;F_N[M_1V"].&E8W]W;D!R/JAB3T2(=9N/<D&LJ*
M1CR?*,:)??KA.^'U2-AGV/Z1ST,.A%MCJT_=!T8:5DB@6*EJ>JJ9D?9&IB)=
MQW *C<V_8T//#\E)\KU%81+-@I"T'J%Y<3&S3VL[V)5;,3-O1?/U HFV(,%\
M>QS6;/BE.  2?7RL:--)<<*H7V1N8HA4,&>LZV,LG)AG!., ZZQ2;A-RF_ Z
M[EWY+4:LF@[^LVZ"NV,//,"]?^$UE"3#2BO46U=M<M6^NOHNYI$P?;QM7']?
M'%OD(T\F!3_(26M, 8.Q=Q&2)?TE-""=(;,P8FH3[A(>!J39IP!D_NGKN+)[
MB:/EL)7#UNZP]?[:LV,85E.E:CE;['3][^7RYM!IZD;)4J6B?<1&;0Y8;PD-
M;XC>1DJS-G[['O'"K":O[5J>#PZKV.@N%KR:WL@-_4G3L^<=4%QNP46GD U]
M[Q'I/'N>>J'>=FU.7;K6X5P?H]PU//ZZ[%TR1_(*<[13IXY :[YPAT'E+B!F
MLI<?%V&5HFQJAI+KP,^@ _=TW(X7V2V!'O,*81;JFE&4];)<->2-&G$8^%M-
MQ<03 :$8K+D)^\PG_QSY/+"Y".6(-6WPNN<@]_10!L?6R/-!CHV44L6S(CP(
M$B$B_)%(W7/Y'8+\VM*=U)%(:S!TO GSA1#GP8M<>]+I=EBJ[BK4 ;=MAWU(
MH9I'TJ?L<[UU6XU>Y[&WG5E6-4E1*YGW]Y2ERI[V]^R1E%&59#4;J0VO,/9#
M299T+56L9(?1=@3N8<.V?18$\7]70$])7,-RH7Z%)\]),_:#&&F*#K]@XI U
M,)0E?K23;^HC[XY!@DWX>./?>T_3V7YE.ML?>@X/SHYFOK=7OHF9P(U_ZWN/
M7*0?2!E+J;Y2+.5H%/+6 \XY_^;#*$05;\*1"W7=5"O&&V+(4>'[2<Q=7!>Z
M]4%C^9 ZI#5FUBCDCXS<],!59L'Z^4ZJCG\\)3P!12*H25EF<B]87WCCB%6T
M[O?A5R:?5R+__FM%5<KG ;EG#AOV/3>9:9]AX,09(?])PV=4"*U&3M*C"%HR
M?'(.-Y1"75/*BZAQFF'OQI4'JGR++9V/@.'!%K5L%E5@W=OL#GPM;=AQCO36
M2G3MA:0QQ$,W.![?K[GI=IZ2DR_@$# _7HWW2?PUQN$SPGNX N\^,)MTT(,@
M5S1(MA=)'WE1?FD+USO!7K//K!]B,QH=@I\U]#E.-;K>F'29XSTA@[$0^4XJ
MQ3](CSL(+CP@'),UV<#XT",!'XR<D+K,&P4P9PEHR(/>1#P9/^!U09FB*%*\
M^<U_WE@Q CH^H>XD*>O!3-][PN?0]^,85 P Q=X-$"+S;#,KCDC71(NQ5J$>
M,/:N2/4[<YD/;DC;!6Z.1!2=-"15.JVE43YCS5:D@UCB5Z5J93]+X/NC5)6E
MLFJ^TF+Z/N9]#1CB#OGF<@M,//G:>=E"7WH7X%\^#P$Q<)E@Y,81Y6!YQM?U
M/*=+8?B' $)3-T%#0*V6=?W\]><N'VN^O9KM,3.A&[/<),.9S=%W(QC NFK$
MZ+JPWQBW&9\H9=+\<D=439:@XHK0_@?>%52M2F6YG'E3$,#,?N*MJF28^Z%4
M521EERCIT2-&QQ-GPZ%G7\$IP4:DA0L]AXOY0YY33I)!S,IEK%!T"O.Q&;B8
M.Y,P!0L=E%+4/#B\J!A:=@]#/+07O-@7)? PJE4]QXLEO+CU&7H7F*!4G#_$
MZ8E_T^MAN"$=;A@Y;LSQ'CA:M&98NM7?4'2[J)YT3].A2%3WX'#$,)7L.&*4
M][.5'7#$W#SX,_@=ZA87)L<14+)V$(R8OP.:F#F:O!!--%;43ZQT:!+7S8(F
MLT&X:01N2R!W(3?/T NXB CYS*&X"+24K><9F03(R,^/T&[@.:-P^9%M"7ZB
M?_O^LQ(\L&+79_1'D?8 %&O4>:*3 +7FU3(+S4.G.7_ V7RW>.;,%#<*,#*?
MV7.:%1\:)HJP4W' $;2IMC[FG[*O6S1GGHJR1.5PXW":(AFRNJ<=0UIE/^9-
M+4L5/5M,[_4;I9F2LN7\SV%L]=ZZ?B.TZ!XO:< QQJC5)Q:FB'L3T_<!.>%3
ML2K;F0RZGG.R88_ <?,A.58K%((EQAS@^*G/X9=GS,YR_&$F@].:,Y$?;7_)
M#BZJ.A<:B\S<1%&[8HQ-?<YRH1Y=VD!$)D9RXGID2'WR2)T1;M]X+3_TYQ-!
M/**C 3WE?Z50O[I:.O:>@L_;&9A+8,T@2.8$44*"Q;D9@LS\[D&E"C@$C?WN
M^3_B89*0.()#6/M@LY8&:U2Y4"\3I53Y&Q$97HD]8IA0Y0VV%QX;BU=BB:H(
M+,GYN;O*9D4&5<V183.;]53(H!7JXOJ;!60P<TW.RN+5R*!'R)#S<V>5S8P,
M1HX,F]ELI$(&LU 7ER[-(X.V^?1[KLDK6+P:&<H"&7)^[JZRF9&ADB/#9C:;
MJ9 !)F7RLL^@O213RL^CR>969-#D"!ER?NZLLEF105-R9-C,YG(:9-!41 8#
MJ,TC@Y9K<E86KT8&+4*&G)\[JVQF9-!S9-C,YDHJ9(!)&5YRN  ,^;0X,X=7
M X,9 4/.SYTU-C,PE'-@V,SF:BI@J*P,0.JYB<O,XM7(4!7(D/-S=Y7-B@RZ
MG"/#ECV\<AIHT!6$AO+B; +O"\M5.2./5V*#KD;84&WD'-U9:S.C@Y:CPQ8^
M*ZG004=T6%J?>%&^YI](EY7MZ& (=,@9^@*ES0P.9@X.6_B<:G.E7D9PT,H+
MX&#FNIR=QZO!(=H]F3/T!4J;&1Q>LADRV\FJMSX+A"DB+9'.:$(LD><(FO6#
M//69R#N_D(2(!P2:R*"K#[A1_\'WGL(^'E$;8F(B"J.=]> 5XN:G*+>&;)#E
MB_R>[^_3IN?3,!=4^5RDV9"-4\QC%1UO4[M%=06)57<!+M+"$V_X^*F4)LO/
M]'01=S&C=TU[OP-:K34,SIA#:6]G0W>Z!"WIQ.^B#\VH"RF/A1KRUF.A[R&7
MY=-O&P^UI2A\\^'>VS" SV#8KD0#OI2-K ]CG3G,"F&LNYXX,S@*F*@%2A'G
M/(.:T2E.,F1X'27*7KS+F>#+GSB\&M7:A;Y!B<\>>0#/ 8)0UT+5I9:%EPAA
MY2"DKDU].XBRG=GK#BQJ)W1Z8'$6(Z0HU]Q4J=;@P1H 6"O#@SAZ6*U(57F7
MZ]@J&VYCF[]F;<=+X?/3Q"E.$V]F$@(F5UA7UBQ3KEBFIANLV^U:BB:#PAL5
MQ:R8VG_ *U]F+.)O$93,IU98"T8#T,C).Z7<;(=L0%1)5B5"[E@P<D*10/@&
M@",^^ [#GWR9(D/3 Z3"@F73_@%1]Q[ B+N1Y4.4 N\H[(,O->TU(F^2D[8U
M[O,N#TFU*BF$AB$%(+8).&,L],[0 ^LRK-8;^2X/L @Y$_3!A HD[C)PP@#@
M;8(9<%7H%G>8+3XKYP*!$1H!.V%0,,'D*7964OM96"DF/ULA?LOI&<*YAP[D
M$R Z"4;=_\([$*?Q08?3+G<B\N*%-)RV8:DO?'K)$?0(K)+/>L )S&+*7:"'
MYB,Q2X* 2(8N$B<D30!<BNY$)H(3<V9C@U_J+>=2.,/#F&PH+CE][AT;#S'/
M*J;T#$4K0;K!R.K'63T/0D$;\VJ&'9Q70]?>)HEYA18S!3 ;PVFZ4L$D>,AA
M-&!GQ!9DDFNF(^,<WS5]!J]SP>Y;J.91>M1DV/O/T-!R.(EN?\#&Q>[E5+__
M&HDK9T49WFY-(I?DDED,4RL331'OTG:23FZO=K=7;VY>%",Q+U5)5L"\/!N1
M3H(5D76)-3[(J!-SKF/DN?UW%(2\-WG[O$LP>:YFSO>H&)GOLEE'J@):HW_D
M=$E[3/F_*=]Q I[7GI0A+'?8?;YD@>7SH;BA<#\1\HV=WX0EO=ZKQ1LW<>""
MKO2L6:0,Y^_>0-+W,5KSEZYJ#EK.@#H,7F2#?71!!,%0ZH? 6K3X%R6Z"._[
MU]]<A*\EPEOA;-U%SM9:;RGQPH2PCZ/CB4-)8E_RB+HFK1F3!VE05R_E*+)^
ML.9R=8^:'K2&W(+W3=JX<@:*AY<@7=*0$G'[ZPG.1VR<FV X5 0&L"I2(G_^
M=G<UG;V>2BF6EEX:CLX+\\*\,"]\U<+5:Z]Y9M'#BZT<R*5PG?;OUXW[;W>M
M3N:F?I0HK8ABW2Y$KGWVUXC[<00K7>C^;-5"KCV">8%%1[CX*L*XOK@;#%_3
M920 ID !+EN$N/C0ITX/X[](2#BQ<04,B+,1AH(%/3H*^YX/O;/7[[Y8O-#Q
MS0-F^DX7I&# K+SY^J+T@;2*4=E/Z$V63#/5G4H+6*H8&U9YW^-:Y.JNGCY8
MDK='&#$R6U=M<M6^NOI.&M>7I'GS];9Q_7U[%.Q#]W0U!IT\W["Y(HOXLG*I
MNRK7\C6P>[A,^V/Q\K=);8Z%;YGD_EUZ+3R=4E BEYY+'9LT)/)O^L/WGH(?
M_!5CQN\G8=Q@ND<9SZ0OE24C=0+3C\63GT7V8EO\3S; 1<<[S.6>3_Z76XQ@
M()KC;KJS>-V5G8D(M'"KFWW.>N"=3C?Y17>#^T>I#I<T9#/7)_P\ZK <DE^4
M[MH=\A]GME_J>O8$_NN' Z?^_U!+ P04    " "+.$98I)A_++D#   ($@
M$    &QL>2TR,#(T,#(P-BYX<V3=5]%RHS84?<]7J#Q7@,#&A@G>:9/9SNYD
MMSMI=KIO.P*$K5F0J"1BY^\KR2:V$VSB::?#-"\!Z9RK>W2/+O+UNTU=@4<B
M).4L=9#K.X"PG!>4+5/GZ\-[.'?>+:ZNKG^"\-NO]W?@EN=M39@"-X)@10JP
MIFH%U(J /[GX01\Q^%)A57)10[BPM!O>/ FZ7"D0^,&D@W6S(O$G93F;SV(X
M)3Z"DWF)8#SU QB5412@. [QI/QYF10Q*O $Q3 L\P!.8CR#\P)E,"I0A(O
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ML6<A'#HZ)]"C4(+<Z-@V@?[@#?6W\Z1QZ$*'[6HZ9+93\'%H"6<'R46#6D[
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MZ,@-7 >5LXYKZ*(,,(OKZ^C=[[3JCRGA?**DCT%+2H*.W6]F@7;SB2(.=^G
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MXT%K]=_ZF%O4/%Y]KO>0\B*JL :NTA\0ZKE$'T;3Q.OS3@R%+\Z?<C!^9?[
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M0W?J?EFNOCW78K,BJV8@:'4.1*8SP%C*0$),1BA3$$GG]S$=&Y^;L'?[3!5
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M-%U@N=3@O)8@T%*:RXDI*_LP\3TCO9B0V\#$8%*.S<0*[72.% &_CB#RY*1
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MPA"QZ<0V(.KX%/;+FQM")S"S>U"M_C!C9#($GX+:0M,^<&!H?\" CZ8$+OO
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M,<<X*P&2%:;[6Q2;^#DEL?8LL5[+O,H"JC?)KUR1W:B8<ENF_ )("/DW#(T
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MHOW)%2@9"SL@+S5'+MY]NGOYW.Q=O[G$[=%@Q#;MU;4K5I?.SJ&]*^P+TS%
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MGH>3P#]E:%N'AW9::S('=TB=\EW2I0[S7B?H#\FA@3*@ ;< ?QX?D&A,(_+
M D9<:C,RB8,P1G!%/KEU63!BGC4EOX6,W,31V _X=XIX)Q>WO]U<$A\L? Z3
MH@$)V"@&4O"#*:'%)\-3IF?[\/1<LN.?DK:D;#($K RHZU"/WW.7#@BU74!U
M"'XBLPF('H\U2AX"?<@B%K*2=R)_Q*(Q"QKB*?$J&T3,\<6S\NH2$OKM)ER+
M2LAQR61-Z'_\0,3.H7Y-/#\B+@/P>:-A[)3D,@A?Y6\1'3BLL"HYUY]_&N#-
MN17OX]Z<!]YNP3H7B?V!V]$X66/QK<21:N:OT &X1G&T_)6%V,2S=:97]I8
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MQ,4/PAL)K\,S P>3!&!AN74XAX%DRT<J8;&S",H:^$M,-TDB$"!@WCT/_,3
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M2PX%GE,F-' 3]WHTJ?X0,GMM;?_MO$]9);SV W!:)KXX5T4B^BT[$7*1I*7
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M;'DM,C R-# R,#8N>'-D4$L! A0#%     @ BSA&6)J__B(1"@  FTP  !0
M             ( !4!<  &QL>2TR,#(T,#(P-E]D968N>&UL4$L! A0#%
M  @ BSA&6, G9?;8$   X:0  !0              ( !DR$  &QL>2TR,#(T
M,#(P-E]L86(N>&UL4$L! A0#%     @ BSA&6,CY,^_+"0  7E$  !0
M         ( !G3(  &QL>2TR,#(T,#(P-E]P<F4N>&UL4$L! A0#%     @
MBSA&6!L4I&?[1P  <>H# !X              ( !FCP  '$T,C-L:6QL>7-A
I;&5S86YD96%R;FEN9W-P+FAT;5!+!08     !@ & (X!  #1A      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>lly-20240206_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20240206"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20240206.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-51">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-52">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-23">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-24">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-25">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-26">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-27">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-28">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-29">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-30">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-31">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-32">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-33">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-34">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-8" id="f-35">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-8" id="f-36">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-8" id="f-37">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-9" id="f-38">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-9" id="f-39">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-9" id="f-40">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-10" id="f-41">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-10" id="f-42">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-10" id="f-43">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-11" id="f-44">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-11" id="f-45">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-11" id="f-46">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-12" id="f-47">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-12" id="f-48">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-12" id="f-49">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-50">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
